EMA：The efficacy of chloroquine against the COVID-19 has not been confirmed

The European Medicines Agency (EMA) New Crown Task Force (COVID-ETF) warns that chloroquine and hydroxychloroquine have not proven effective in treating new coronary pneumonia, and their side effects can be fatal.

 

The new crown task force said in a statement that the use of chloroquine and hydroxychloroquine to treat new coronavirus pneumonia is still being tested. The therapeutic effects of these drugs have not been confirmed, but their side effects have been confirmed.

 

The working group said that studies of chloroquine and hydroxychloroquine have shown to cause heart rhythm problems due to disturbances in human electrical activity. Such drugs, if taken in high doses or used with other drugs, such as the azithromycin antibiotic, which has a similar effect on the heart, may cause death.

 

Chloroquine and hydroxychloroquine are currently approved for the treatment of malaria and some autoimmune diseases. Other known side effects include liver and kidney problems, which can cause nerve cell damage in epilepsy and hypoglycemia.

 

Both drugs are undergoing clinical trials to test their efficacy and safety in treating new coronary pneumonia. However, the working group emphasized that the clinical data obtained are still limited and uncertain, and the effect of the drug has yet to be proven.

 

Some clinical trials are investigating chloroquine and hydroxychloroquine (treatment of new crowns) at higher doses than recommended for the approved indications, which may increase the risk of serious side effects.

 

The working group also pointed out that medical professionals should closely monitor patients with new coronary pneumonia taking chloroquine or hydroxychloroquine, and consider pre-existing heart diseases when prescribing them. These diseases may make patients more prone to heart rhythm problems. It should also be used with caution in combination with other drugs such as azithromycin, because these drugs may have similar side effects on the heart. The working group said that these drugs should only be used as part of clinical trials for patients with new coronary pneumonia, and should be used under prescription and doctor supervision.

 

The working group concluded that patients and health care professionals should report any possible side effects to their national regulatory authorities, and stated that the European Medicines Agency and national regulatory authorities are closely monitoring the progress of (clinical trials) of various new coronary pneumonia potential drugs To speed up their development.